title: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
abstract: OBJECTIVE
  To evaluate the ability of epithelial-to-mesenchymal transition-related microRNAs (miRNAs) as serum biomarkers for prognosis and prediction of metastasis in patients with colorectal cancer (CRC).
  
  
  BACKGROUND
  Epithelial-to-mesenchymal transition-related miRNAs drive CRC progression and metastasis. However, their potential as serum biomarkers in CRC has not been studied.
  
  
  METHODS
  This was a 3-phase study using 446 colorectal specimens. In the first phase, we selected candidate miRNAs associated with metastasis by analyzing the expression of 4 miR-200 family members (miR-200b, -200c, -141, and -429) in serum samples from 12 patients with stage I and IV CRC. The second phase involved independent validation of candidate miRNAs in serum from 182 patients with CRC and 24 controls. Finally, we analyzed expression in matched 156 tumor tissues from 182 patients with CRC and an independent set of 20 matched primary CRC and corresponding liver metastases to identify the source of circulating miRNAs.
  
  
  RESULTS
  After initial screening, miR-200c was selected as the candidate serum miRNA best associated with metastasis. Validation analysis revealed that serum miR-200c levels were significantly higher in stage IV than in stage I-III CRCs. High serum miR-200c demonstrated a significant positive correlation with lymph node metastasis, distant metastasis, and prognosis (P = 0.0026, P = 0.0023, and P = 0.0064, respectively). More importantly, serum miR-200c was an independent predictor for lymph node metastasis (odds ratio: 4.81, 95% confidence interval: 1.98-11.7, P = 0.0005) and tumor recurrence (hazard ratio: 4.51, 95% confidence interval: 1.56-13.01, P = 0.005) and emerged as an independent prognostic marker for CRC (hazard ratio: 2.67, 95% confidence interval: 1.28-5.67, P = 0.01).
  
  
  CONCLUSIONS
  Serum miR-200c has strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting metastasis.
authors: *Gastrointestinal Cancer Research Laboratory, Division of Gastroenterology, Department of Internal Medicine, Charles A. Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, TX †Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan.
authors: Yuji
authors: Y
authors: Toiyama
authors: Keun
authors: K
authors: Hur
authors: Koji
authors: K
authors: Tanaka
authors: Yasuhiro
authors: Y
authors: Inoue
authors: Masato
authors: M
authors: Kusunoki
authors: C Richard
authors: CR
authors: Boland
authors: Ajay
authors: A
authors: Goel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000235:genetics / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C533896:MIRN200 microRNA, human; D035683:MicroRNAs
references: Oncology (Williston Park). 2006 May;20(6):579-87; discussion 588, 594, 596 passim
references: 16773844
references: Mod Pathol. 2004 May;17(5):503-11
references: 15001992
references: Int J Cancer. 2010 Jul 1;127(1):118-26
references: 19876917
references: Expert Opin Biol Ther. 2009 Jun;9(6):703-711
references: 19426115
references: Gastroenterology. 2012 Sep;143(3):844-857
references: 22763141
references: J Cell Physiol. 2007 Nov;213(2):374-83
references: 17680632
references: Nat Cell Biol. 2009 Dec;11(12):1487-95
references: 19935649
references: Gut. 2009 Oct;58(10):1375-81
references: 19201770
references: BMC Cancer. 2010 Apr 29;10:173
references: 20429937
references: Gut. 2013 Sep;62(9):1315-26
references: 22735571
references: Nat Rev Cancer. 2011 Aug 05;11(9):644-56
references: 21822212
references: Cancer Epidemiol. 2012 Feb;36(1):e61-7
references: 22018950
references: Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1766-74
references: 20551304
references: J Clin Oncol. 2007 Jan 10;25(2):180-6
references: 17210937
references: Surg Oncol. 2009 Mar;18(1):15-24
references: 18619834
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Biom J. 2008 Jun;50(3):419-30
references: 18435502
references: Gastroenterology. 2006 Sep;131(3):830-40
references: 16952552
references: PLoS One. 2011 Mar 17;6(3):e17745
references: 21445232
references: EMBO Rep. 2008 Jun;9(6):582-9
references: 18483486
references: Anticancer Res. 2008 Nov-Dec;28(6B):4111-5
references: 19192669
references: Nat Rev Cancer. 2002 Jun;2(6):442-54
references: 12189386
references: Anticancer Res. 2000 Nov-Dec;20(6D):5195-8
references: 11326694
references: J Gastroenterol Hepatol. 2010 Oct;25(10):1674-80
references: 20880178
references: Cell. 2009 Nov 25;139(5):871-90
references: 19945376
references: Methods. 2010 Apr;50(4):298-301
references: 20146939
references: Clin Chem. 2001 Apr;47(4):624-30
references: 11274010
references: Eur J Cancer. 2007 Jun;43(9):1348-60
references: 17512720
references: Dis Colon Rectum. 2005 Jan;48(1):92-100
references: 15690664
references: Nat Cell Biol. 2008 May;10(5):593-601
references: 18376396
references: Nat Rev Cancer. 2009 Apr;9(4):265-73
references: 19262571
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219